Merck KGaA third-quarter net sales rise 1.0% to €5.3 billion

Reuters

Nov 13

<a href="https://laohu8.com/S/MKGAF">Merck KGaA</a> third-quarter net sales rise 1.0% to €5.3 billion

Merck KGaA reported net sales of €5.3 billion for the third quarter of 2025, reflecting organic growth of 5.2%. Foreign exchange effects reduced net sales by 4.9%, while portfolio effects added 0.7%. EBITDA pre increased organically by 8.8% to €1.7 billion, with foreign exchange effects of -6.5% and portfolio effects of +0.9%. Growth was mainly driven by the Process Solutions segment in Life Science, Rare Diseases in Healthcare, and Semiconductor Solutions in Electronics. The Healthcare sector saw organic sales growth of 4.6%, supported by strong performance in Cardiovascular, Metabolism & Endocrinology and sales of Mavenclad and Erbitux. The acquisition of SpringWorks Therapeutics contributed to positive portfolio effects, establishing Rare Diseases as a new strategic focus. Merck KGaA confirmed its guidance for the full year 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583530615"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583530615\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583530615?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 14:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583530615","market":"us","top_or_hot":-1,"title":"Merck KGaA third-quarter net sales rise 1.0% to €5.3 billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> third-quarter net sales rise 1.0% to €5.3 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> reported net sales of €5.3 billion for the third quarter of 2025, reflecting organic growth of 5.2%. Foreign exchange effects reduced net sales by 4.9%, while portfolio effects added 0.7%. EBITDA pre increased organically by 8.8% to €1.7 billion, with foreign exchange effects of -6.5% and portfolio effects of +0.9%. Growth was mainly driven by the Process Solutions segment in Life Science, Rare Diseases in Healthcare, and Semiconductor Solutions in Electronics. The Healthcare sector saw organic sales growth of 4.6%, supported by strong performance in Cardiovascular, Metabolism &amp; Endocrinology and sales of Mavenclad and Erbitux. The acquisition of SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> contributed to positive portfolio effects, establishing Rare Diseases as a new strategic focus. Merck KGaA confirmed its guidance for the full year 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck KGaA third-quarter net sales rise 1.0% to €5.3 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck KGaA third-quarter net sales rise 1.0% to €5.3 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 14:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> third-quarter net sales rise 1.0% to €5.3 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> reported net sales of €5.3 billion for the third quarter of 2025, reflecting organic growth of 5.2%. Foreign exchange effects reduced net sales by 4.9%, while portfolio effects added 0.7%. EBITDA pre increased organically by 8.8% to €1.7 billion, with foreign exchange effects of -6.5% and portfolio effects of +0.9%. Growth was mainly driven by the Process Solutions segment in Life Science, Rare Diseases in Healthcare, and Semiconductor Solutions in Electronics. The Healthcare sector saw organic sales growth of 4.6%, supported by strong performance in Cardiovascular, Metabolism &amp; Endocrinology and sales of Mavenclad and Erbitux. The acquisition of SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> contributed to positive portfolio effects, establishing Rare Diseases as a new strategic focus. Merck KGaA confirmed its guidance for the full year 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SWTX","symbol_name":"SpringWorks Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL7ztz5W:1","article_id":"2583530615","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583530615","pubTimestamp":1763013678,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Merck KGaA reported net sales of 5.3 billion for the third quarter of 2025, reflecting organic growth of 5.2%. Foreign exchange effects reduced net sales by 4.9%, while portfolio effects added 0.7%. EBITDA pre increased organically by 8.8% to 1.7 billion, with foreign exchange effects of -6.5% and portfolio effects of +0.9%. Growth was mainly driven by the Process Solutions segment in Life Science, Rare Diseases in Healthcare, and Semiconductor Solutions in Electronics. The Healthcare sector saw organic sales growth of 4.6%, supported by strong performance in Cardiovascular, Metabolism & Endocrinology and sales of Mavenclad and Erbitux. The acquisition of SpringWorks Therapeutics contributed to positive portfolio effects, establishing Rare Diseases as a new strategic focus. Merck KGaA confirmed its guidance for the full year 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SWTX":"SpringWorks Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"默克集团第三季度净销售额增长1.0%至53亿欧元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SWTX":0.9},"content_text":"Merck KGaA third-quarter net sales rise 1.0% to €5.3 billion\n    \n\nMerck KGaA reported net sales of €5.3 billion for the third quarter of 2025, reflecting organic growth of 5.2%. Foreign exchange effects reduced net sales by 4.9%, while portfolio effects added 0.7%. EBITDA pre increased organically by 8.8% to €1.7 billion, with foreign exchange effects of -6.5% and portfolio effects of +0.9%. Growth was mainly driven by the Process Solutions segment in Life Science, Rare Diseases in Healthcare, and Semiconductor Solutions in Electronics. The Healthcare sector saw organic sales growth of 4.6%, supported by strong performance in Cardiovascular, Metabolism & Endocrinology and sales of Mavenclad and Erbitux. The acquisition of SpringWorks Therapeutics contributed to positive portfolio effects, establishing Rare Diseases as a new strategic focus. Merck KGaA confirmed its guidance for the full year 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}